Application of peimine in preparation of medicine for preventing and/or treating ulcerative colitis

A technology for ulcerative colitis and fritillin A, which is applied in the field of medicine, can solve the problems of anti-ulcerative colitis and other problems that no fritillin A has ever seen, and achieve excellent anti-ulcerative colitis activity, prevention and intestinal tissue pathology. Injury, the effect of reducing the rate of weight loss

What is AI technical title?
AI technical title is built by PatSnap AI team. It summarizes the technical point description of the patent document.
A technology for ulcerative colitis and fritillin A, which is applied in the field of medicine, can solve the problems of anti-ulcerative colitis and other problems that no fritillin A has ever seen, and achieve excellent anti-ulcerative colitis activity, prevention and intestinal tissue pathology. Injury, the effect of reducing the rate of weight loss

CN113143939AInactive Publication Date: 2021-07-23CHANGCHUN UNIV OF CHINESE MEDICINE +1

3 Cites 2 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.

Viewing Examples

Smart Image

Examples

Experimental program

Comparison scheme

Effect test

Embodiment 1

[0048] Embodiment 1 Peiminin A Safety Experiment

[0049]Eighteen healthy male C57BL / 6J mice with a body weight of about 20 g were randomly divided into 3 groups, 6 in each group, namely the control group, the peimin A (2mg / kg) group and the peimin A (6mg / kg) group. Group. After adapting to the environment for one week, prepare peimin A with physiological saline, and administer it according to the body weight of the experimental mice every day. Perimrin A (6 mg / kg) group was administered 6 mg / kg of peimin A by intragastric administration, and the control group was administered intragastrically with 100 μ L of normal saline for 7 days. At the same time, the death, body weight, intestinal tissue, Cases of colon and cecum pathology.

[0050] Experimental results such as figure 1 , figure 2 , image 3 and Figure 4 shown. The results showed that the administration of peiminine did not cause significant impact on the experimental mice, that is, compared with the normal sali...

Embodiment 2

[0051] The influence of embodiment 2 peiminine A on the disease symptoms of ulcerative colitis mice

[0052] Fifty healthy male C57BL / 6J mice weighing about 20 g were randomly divided into 5 groups, 10 in each group, namely control group, model group, positive drug group, peimin A (2 mg / kg) group and peimin A (6mg / kg) group. After adapting to the environment for one week, the mice were administered daily according to their body weight. The control group drank normal water and administrated 100 μL of normal saline. / kg, the peiminin (6mg / kg) group was given 6mg / kg by intragastric administration of peiminin A, the model group was given intragastric administration of 100 μ L of normal saline, and the positive drug group was given 5-aminosalicylic acid by intragastric administration of 150mg / kg. kg, continuous administration for 7 days. After administration on the first day, 3% dextran sodium sulfate (Dextran Sulfate Sodium Salt, DSS) was added to the drinking water of the exper...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

PUM

Login to View More

Abstract

The invention discloses application of peimine in preparation of a medicine for preventing and / or treating ulcerative colitis, and relates to the field of medicines. According to the invention, experiments prove that the peimine has no significant influence on experimental mice: the experimental mice of a peimine group have no death; the weight has no significant change; the intestinal tissue has no obvious lesion; the colon and the cecum have no obvious pathological symptoms; and the peimine has certain safety. The peimine can reduce the weight loss rate of a mouse with the ulcerative colitis, can improve the fecal character and hemafecia condition of the mouse with the ulcerative colitis, can improve DAI of the mouse with the ulcerative colitis, and can effectively prevent and improve pathological damage of intestinal tissues of the mouse with the ulcerative colitis; therefore, the peimine has particularly excellent ulcerative colitis resisting activity and certain safety, and can obviously improve the ulcerative colitis symptom.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of peiminin A in the preparation of medicines for preventing and / or treating ulcerative colitis. Background technique [0002] Ulcerative colitis is a chronic nonspecific intestinal inflammatory disease whose etiology is not yet clear, characterized by continuous and diffuse inflammatory changes in the colorectal mucosa, and its lesions are mainly limited to the large intestinal mucosa and submucosa. The clinical manifestations are diarrhea, mucus pus and blood in the stool, and abdominal pain, and it is mostly a chronic course of repeated attacks. [0003] At present, the clinical treatment of ulcerative colitis is based on the course of the disease, and aminosalicylic acid preparations (5-aminosalicylic acid or sulfasalazine, etc.), corticosteroids (prednisone or hydrocortisone, etc.) or Immunosuppressant (azathioprine or 6-mercaptopurine, etc.) to be treated....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine

Login to View More

Application Information

Patent Timeline

23 Jul 2021

Publication

CN113143939A

IPC: A61K31/58; A61P1/04; A61P1/00; A61P29/00

CPC: A61K31/58; A61P1/04; A61P1/00; A61P29/00

Inventors: 朱羿龙; 韩继成